Nyxoah FY2025 EPS Forecast Reduced by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has revised its FY2025 EPS estimates for Nyxoah to ($2.53), a decrease from the previous estimate of ($2.36).
• The company's recent quarterly earnings revealed a reported EPS of ($0.63), which missed the consensus estimate of ($0.62).
• In the second quarter, various institutional investors have increased their positions in Nyxoah, indicating growing interest in the company despite its financial challenges.

Nyxoah SA (NASDAQ:NYXH - Free Report) - Investment analysts at Cantor Fitzgerald dropped their FY2025 earnings estimates for shares of Nyxoah in a report released on Wednesday, August 20th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will earn ($2.53) per share for the year, down from their prior forecast of ($2.36). The consensus estimate for Nyxoah's current full-year earnings is ($1.91) per share. Cantor Fitzgerald also issued estimates for Nyxoah's FY2026 earnings at ($1.61) EPS.

Nyxoah Trading Down 3.2%

NASDAQ NYXH traded down $0.21 during trading on Friday, hitting $6.20. The company had a trading volume of 34,577 shares, compared to its average volume of 105,589. The company has a current ratio of 2.63, a quick ratio of 2.38 and a debt-to-equity ratio of 0.29. Nyxoah has a one year low of $5.55 and a one year high of $11.87. The company has a market cap of $211.00 million, a price-to-earnings ratio of -2.69 and a beta of 1.61. The company's fifty day moving average is $7.39 and its 200-day moving average is $7.81.

Nyxoah (NASDAQ:NYXH - Get Free Report) last issued its quarterly earnings data on Monday, August 18th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.01). Nyxoah had a negative return on equity of 79.18% and a negative net margin of 1,541.84%.The company had revenue of $1.58 million during the quarter, compared to the consensus estimate of $1.33 million.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of NYXH. LPL Financial LLC bought a new position in shares of Nyxoah in the 4th quarter worth about $102,000. Geode Capital Management LLC increased its stake in shares of Nyxoah by 19.4% in the 4th quarter. Geode Capital Management LLC now owns 17,100 shares of the company's stock worth $137,000 after acquiring an additional 2,774 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of Nyxoah in the 4th quarter worth about $187,000. Walleye Capital LLC increased its stake in shares of Nyxoah by 23.9% in the 4th quarter. Walleye Capital LLC now owns 14,831 shares of the company's stock worth $119,000 after acquiring an additional 2,862 shares in the last quarter. Finally, Ameriprise Financial Inc. bought a new position in shares of Nyxoah in the 4th quarter worth about $135,000.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.